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European Medicines Agency (EMA) and Food 
and Drug Administration (FDA) have the most 
powerful contribution to the development of law 
registration and efficient implementation of Polypill 
(and variety formulations with might be defined as 
fixed dose combination [FDC]) into clinical practice. 
Fixed-dose combinations are the consequence of 
evolution in pharmaceutical technology [1, 2]. The 
first attempt of applying a FDC in human clinical 
settings has been observed since the 70s. Accord-
ing to World Health Organization (WHO) experts, 
FDC in the secondary prevention of cardiovascular 
events are strongly recommended. Accordingly, 
FDA and EMA highlighted the potential benefits for 
the patient from the use of FDC regarding its clini-
cal efficacy, low cost of therapy, and improving the 
adherence [3, 4]. Current European guidelines on 
cardiovascular diseases (CVD) prevention also rec-
ommend using FDC, due to patient convenience [5]. 
Currently, there is still no uniform and accepted 
definition of a Polypill. The early concept of Polypill 
was developed from combination of 5–6 active 
pharmaceutical ingredients (APIs) to formulation 
containing acetylsalicylic acid (ASA), statin and one 
antihypertensive agent (ramipril), which is the first 
Polypill approved in several Latin American and 
European markets under the trade names Trino-
mia®, Sincronium®, or Iltria® (Ferrer International, 
Spain) [6]. According to the Fuster-CNIC-Ferrer 
concept, Polypill is defined as an oral dosage form 
containing a low dose of ASA, statin, and at least 
one antihypertensive drug used in the prevention 
of cardiovascular events [7, 8].
According to WHO guidelines 2005 [9]  for 
registration of FDC medicinal products, Polypill 
as FDC comprised of APIs of well-established use 
may be a subject of the three considered scenarios 
of the registration process, i.e. i) as a generic drug 
for existing FDC with established quality, safety, 
and efficacy; ii) as FDC of single entity products 
used together in a well-established therapeutic 
regime; iii) as FDC of APIs, which have not been 
previously used in combination to prevent CVD 
or a combination of well-established use, but in 
a different therapeutic regimen. Depending on the 
scenario, appropriate set of documentation in the 
registration process should be included; the most 
detailed documentation is required if Polypill is the 
subject of scenario III. In this case, an inclusion 
of rational justification of introducing it onto the 
market, estimating the benefits and risks of the 
proposed formulation and evaluation of safety and 
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clinical efficacy in the registration dossier remains 
obligatory. However, in the case of scenario I and II, 
an applicant is obliged to perform the bioequiva-
lence studies. Pre-clinical pharmacology and safety 
studies are not usually required in case of Polypill. 
Some of those requirements may be fulfilled by 
presenting relevant literature data [9]. 
In 2006, FDA issued guidance on registration 
of antiretroviral FDC, whereas there is no such 
a regulation for Polypills. The Agency is planning 
to release a general guide representing the FDA 
view on requirements for the registration process 
of FDC. According to FDA, a FDC is a formulation 
comprising at least two APIs available on the mar-
ket as single entity products. An applicant is obliged 
to include the non-clinical safety assessment of the 
FDC in the registration dossier. Pharmacodynamic 
and toxicology additional non-clinical safety test-
ing is not recommended before clinical trials for 
therapeutic regimens which are well known for 
safety of individual API and potential chemical 
interaction. In contrast, studies of potential toxic-
ity to the developing embryo and fetus are recom-
mended regardless of the knowledge of the toxic 
potential of APIs. Carcinogenicity study of FDC 
is recommended if such a potential was noticed 
during non-clinical studies. Bioequivalence stud-
ies are an obligation of a Marketing Authorization 
Holder (MAH) during the registration process 
of a generic drug. Once the data obtained from 
non-clinical studies do not suggest an interaction 
potential, testing on animals may be omitted before 
the clinical trials. In practice, FDA does not re-
quire clinical trials for registration of FDCs, which 
consist of APIs with well-established concomitant 
use. ASA-pravastatin and atorvastatin-amlodipine 
combinations were registered after establishing 
the lack of pharmacokinetic and pharmacodynamic 
interactions between the APIs [4].
According to the Directive 2001/83/EC of the 
European Parliament and of the Council of 6 No-
vember 2001 (OJ L 311, 28.11.2001, p. 67), the en-
tity applying for registration of a medicinal product 
is not obliged to provide the results of toxicological 
and pharmacological tests or clinical trials when 
the components of the medicinal product have 
well-established medicinal use, with recognized 
efficacy and an acceptable level of safety based on 
literature data. In case of medicinal products regis-
tration containing known APIs which have not been 
used together in a given therapeutic indication, 
MAH is obliged to provide the results of toxicologi-
cal and pharmacological tests, as well as clinical 
trials of the FDC. EMA guidelines of 2008 [10] 
govern non-clinical studies on the development 
of FDC medicinal products. In case of combined 
APIs of well-established use and with documented 
lack of interaction between the components, it is 
not required to conduct non-clinical studies. For 
well-established APIs, yet the undocumented 
use of their combination, the performance of an 
adequate non-clinical toxicology, pharmacokinetic 
and pharmacological studies is recommended [10].
Clinical studies during the development of 
FDC are also governed by the relevant guidelines 
(currently under revision). The joint use of Polypill 
components must have a rationale and provide 
tangible benefits in comparison with potential risks 
associated with the FDC. All of the APIs must have 
a proven action in the given indication, known 
safety profile and established pharmacokinetic and 
pharmacodynamic interactions. MAH can prove 
the action by presenting the results of clinical tri-
als of Polypill and/or a combination of single entity 
products based on literature data or by comparing 
the results of clinical trials with literature data. 
In case of the FDC containing at least three 
APIs such as Polypill, an applicant during the 
registration process must assess: i) potential for 
drug–drug interactions — pharmacokinetic stud-
ies in humans may be omitted if the appropriate in 
vitro test is conducted or a combination of APIs is 
of well-established use in medicine with specific 
safety profile or well-known pharmacokinetic and 
drug–drug interactions profile; ii) pharmacody-
namic data — the entity is not obliged to carry 
out those tests, if present relevant clinical data 
concerning the efficacy and safety of used poly-
therapy; iii) the efficacy and safety of FDC, which 
must be higher than polypharmacy of single entity 
products; iv) bioequivalence of FDC to the single 
entity drugs according to EMA guidelines. In case 
of a new therapeutic regimen or different doses of 
Polypill in relation to single entity drugs, a similar 
pharmacokinetic profile and an evidence of the 
effectiveness of the proposed FDC must be well 
documented and strictly reported. In addition, an 
applicant should consider clinical safety issues. If 
the combination of APIs has new indications, the 
registration of the drug as an entirely new clinical 
development should be conducted [10].
The registration process of Polypill in both 
United States and European Union remains chal-
lenging and falls under many regulations related to 
FDC medicinal products. The FDA and the EMA 
requirements are similar and in case of Polypill 
consisting of APIs of well-established use under 
therapeutic regimen may be fulfilled mostly by 
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literature. Indeed, the Polypill registration process 
may differ according to the law interpretation taken 
by the MAH and will be revised in the industrial 
regulatory practice.
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